Leibniz-Institut für Virologie

What Leibniz-Institut für Virologie does

Leibniz-Institut für Virologie (LIV) is a German non-profit research institute organized as a Stiftung bürgerlichen Rechts under German civil law, headquartered in Hamburg adjacent to the University Medical Center Hamburg-Eppendorf (UKE). Founded in 1948 and operating with 101–250 staff, it is a member of the Leibniz Association (Leibniz-Gemeinschaft), a network of publicly funded non-university research institutes. LIV's mission is to characterize the molecular mechanisms of human-pathogenic viruses — including HIV-1, hepatitis C, influenza, and emerging viruses with pandemic potential — and to translate those insights into new therapeutic and preventive strategies, with particular emphasis on protective immunity, sex-specific immune responses, and pandemic preparedness.

The institute's research is organized around scientific departments (notably Virus Immunology led by Prof. Dr. Marcus Altfeld and Integrative Virology led by Prof. Dr. Maya Topf) and a set of shared technology platforms: flow cytometry/FACS, next-generation sequencing, small animal models, light and electron microscopy (including cryo-EM access via the Centre for Structural Systems Biology/CSSB with DESY), and scientific computing for bioinformatics and integrative modeling. AI-based structural-modeling methods are used to predict and evaluate viral macromolecular complexes, including the ChemEM docking tool for cryo-EM structures. LIV also runs a graduate school and the Leibniz Center Infection (LCI) summer school for training the next generation of virologists.

LIV does not sell commercial products or services; its revenue model is public research funding from German federal and state governments via the Leibniz Association, supplemented by third-party grants. Customer segments are academic and public-sector: the scientific research community (collaborative projects, publications, conferences), the public health sector (pandemic preparedness, infectious disease monitoring), and students/early-career researchers (graduate and postdoctoral training). Distribution of outputs occurs through peer-reviewed publications (including Nature and Cell Reports), scientific collaborations, international conferences and workshops (e.g., the 28th International Workshop on KSHV & Related Agents), the institute's website, newsletters, and active social media across X, Facebook, Instagram, LinkedIn, YouTube, and Bluesky. Strategic partners include Universität Hamburg, UKE, DESY/CSSB, Bernhard-Nocht-Institut für Tropenmedizin, Forschungszentrum Borstel, DZIF, Leibniz Center Infection, InterACt, DZKJ, and the Leibniz-Lab Pandemic Preparedness network, the last of which LIV coordinates.

Name

Leibniz-Institut für Virologie

Legal name

Leibniz-Institut für Virologie - Stiftung bürgerlichen Rechts

Website

https://leibniz-liv.de

Company type

Private

Founded year

1948

Operating status

Operating

Headcount range

101–250 employees

Short description

Leibniz-Institut für Virologie is a Hamburg-based, publicly funded German research institute studying human-pathogenic viruses (HIV-1, HCV, influenza, emerging viruses) to develop new therapeutic and preventive approaches, serving the academic research community, public health sector, and early-career scientists.

Ownership category

akta.pro rank

Product category

Virology and Infectious Disease Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Health Security, Pandemic Preparedness & Response (IHR, EID) (BPADAIAH)

akta.pro secondary industries

Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC), Modeling, Forecasting & Risk Assessment for Outbreaks (HLAJABAM)

Keywords

• Virology research
• Viral immunology
• Structural biology
• Pandemic preparedness
• Infectious disease research

Headquarters

HQ city

Hamburg

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Others

Revenue model

1. Public Research Funding: Funded by German federal and state governments as part of the Leibniz Association (Leibniz-Gemeinschaft), a publicly funded research organization.

Distribution channels2 records

Marketing channels6 records

Core offering

Leibniz-Institut für Virologie (LIV) is a publicly funded German research foundation that conducts fundamental and translational research on human-pathogenic viruses, including HIV-1, Hepatitis C, influenza, and emerging viruses with pandemic potential. Its work spans molecular virology, viral immunology, integrative structural biology, and systems biology, and is supported by shared technology platforms (cryo-EM, NGS, FACS, small animal models, microscopy, scientific computing) and graduate training programs. Outputs are scientific knowledge, publications, therapeutic and preventive concepts, and pandemic preparedness contributions rather than commercial products.

Product overview

The Leibniz-Institut für Virologie is a research institute (Stiftung bürgerlichen Rechts) that does not offer commercial products but provides research services and technology platforms. The institute conducts fundamental research on human pathogenic viruses with the goal of understanding virus-induced diseases and developing new therapeutic approaches. The core offerings include specialized research departments (Virus Immunology, Integrative Virology) and shared technology platforms including Flow Cytometry/FACS, Next Generation Sequencing, Small Animal Models, Microscopy and Image Analysis, and Scientific Computing. Training services include the LIV Graduate School and LCI Program & Summer School. The Integrative Virology department uses AI-based integrative modeling methods for viral structure analysis.

Differentiator

Problem solved

Functional benefit

Products and services

• Virus Immunology (Virusimmunologie) Research Department
• Integrative Virology (Integrative Virologie) Research Department Research department specializing in integrative modeling methods for elucidating structures of large macromolecular viral complexes, using AI-based approaches for structure prediction and model evaluation, including the ChemEM software for flexible docking of small molecules in cryo-EM structures. For the structural biology and virology research community.
• Flow Cytometry / FACS Technology Platform Shared technology platform providing flow cytometry and fluorescence-activated cell sorting (FACS) capabilities for analyzing immune cell populations and virus-host interactions. Available to internal and collaborative research users.
• Next Generation Sequencing (Hochdurchsatz-Sequenzierung) Technology Platform Shared technology platform providing high-throughput sequencing for viral genomics, transcriptomics, and metagenomics analysis. Available to internal and collaborative research users.
• Small Animal Models (Kleintiermodelle) Platform In vivo laboratory for studying viral pathogenesis and therapeutic interventions in small animal models. Available to internal and collaborative research users.
• Microscopy and Image Analysis Platform Advanced light and electron microscopy platforms for visualizing viral structures, including the cryo-electron microscopy facility at CSSB. Available to internal and collaborative research users.
• Scientific Computing Platform High-performance computing and bioinformatics infrastructure for data analysis, computational modeling, and processing of large-scale virology datasets. Available to internal and collaborative research users.
• LIV Graduate School (LIV-Graduiertenschule) Structured doctoral training program in virology and related biomedical disciplines for PhD candidates at LIV.
• LCI Program & Summer School Leibniz Center Infection training program and summer school for young researchers in infection research, offered by LIV in cooperation with partner institutions.

Quantifiable outcome

• Publications in high-impact journals including Nature, Cell Reports, and others
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature7 records

Partnerships

14 partnerships are on record, tiered core and secondary.

• Bernhard-Nocht-Institut für TropenmedizincoreStrategic or Co-development PartnerPartner in infectious disease research network in Hamburg. Both institutes collaborate on tropical medicine and virology research topics.
• Deutsches Elektronen-Synchrotron (DESY)coreStrategic or Co-development PartnerCollaborates through the Centre for Structural Systems Biology (CSSB) for advanced structural biology research using synchrotron radiation.
• Forschungszentrum BorstelcoreStrategic or Co-development PartnerPartner in tuberculosis and infectious disease research. Collaborates within the DZIF (German Centre for Infection Research) network.
• Universität HamburgcoreStrategic or Co-development PartnerMajor academic partner. Multiple joint professorships including W2 professorship for Systembiologie der Viren (Prof. Pietro Scaturro) and W3 professorship for Emerging Viruses (Prof. Stephanie Pfänder).
• Universitätsklinikum Hamburg-Eppendorf (UKE)coreStrategic or Co-development PartnerAdjacent to the UKE campus. Prof. Marcus Altfeld holds a position at UKE. Close integration with clinical research and medical faculty.
• Stiftung Tierärztliche Hochschule HannoversecondaryStrategic or Co-development PartnerCollaboration in veterinary infectious diseases and One Health research approaches.
• Deutsches Zentrum für Infektionsforschung (DZIF)coreStrategic or Co-development PartnerLIV is part of the DZIF network, specifically the Hamburg-Lübeck-Borstel-Riems site. Prof. Marcus Altfeld serves as site spokesperson.
• Leibniz-Gemeinschaft (Leibniz Association)coreStrategic or Co-development PartnerLIV is a member of the Leibniz Association, a network of non-university research institutions funded by federal and state governments.
• Leibniz-Lab Pandemic PreparednesscoreStrategic or Co-development PartnerCross-institutional initiative of the Leibniz Association focused on preparing for future pandemics. LIV coordinates this initiative connecting interdisciplinary research.
• Centre for Structural Systems Biology (CSSB)coreStrategic or Co-development PartnerJoint facility with cryo-EM infrastructure shared between LIV, DESY, and other partner institutions. Provides advanced structural biology capabilities.
• InterACt Leibniz-WissenschaftsCampussecondaryStrategic or Co-development PartnerScienceCampus initiative fostering interdisciplinary research collaborations in infectious disease research.
• Leibniz Center InfectionsecondaryStrategic or Co-development PartnerNetwork of Leibniz institutions focused on infectious disease research within the Leibniz Association.
• Deutsches Zentrum für Kinder- und Jugendgesundheit (DZKJ)secondaryStrategic or Co-development PartnerCollaboration in child and adolescent health research with focus on infectious diseases affecting young populations.
• PIER PLUSsecondaryStrategic or Co-development PartnerPartnership platform for interdisciplinary research and innovation in the Hamburg metropolitan region.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Charité – Universitätsmedizin Berlin: One of Europe's largest university hospitals with major virology and infectious disease research departments; comparable as a German biomedical research powerhouse in infectious disease.
• Max Planck Institute for Multidisciplinary Sciences: German Max Planck society institute with research programs in structural biology and infection biology; comparable to LIV as a German publicly funded basic biomedical research organization.
• European Molecular Biology Laboratory (EMBL): Intergovernmental research organization in life sciences with strong structural biology programs; comparable to LIV as a publicly funded European life-sciences research institution using cryo-EM and computational methods.
• Robert Koch Institute (RKI): German federal government agency for disease control and prevention; overlaps with LIV on infectious disease surveillance, pandemic preparedness, and epidemiological research at a national policy scale.
• National Institute of Allergy and Infectious Diseases (NIAID/NIH): U.S. federal institute conducting large-scale virology, immunology, and emerging infectious disease research; comparable to LIV in mission focus but at vastly larger scale and with global mandate.
• Pasteur Institute: Major French non-profit biomedical research center with deep historical focus on virology, immunology, and emerging infectious diseases; comparable mission profile to LIV at larger scale.

Direct peers

• Bernhard-Nocht-Institut für Tropenmedizin: German tropical medicine and virology research institute based in Hamburg; explicit collaboration partner of LIV with shared focus on infectious disease and tropical virology.
• Helmholtz Centre for Infection Research (HZI): Large German publicly funded research center focused on infection biology; comparable to LIV as a non-university research institute working on infectious disease mechanisms and therapeutics.
• Friedrich-Loeffler-Institut (Federal Research Institute for Animal Health): German federal institute conducting virology research on animal and zoonotic viruses; comparable in mission scope as a publicly funded virology research center.

Regional players

• Karolinska Institutet: Swedish medical university with major virology and immunology departments; comparable to LIV in basic virology research mission but operating primarily in Sweden/Scandinavia rather than Germany.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/LeibnizLIV
• YouTubeyoutube.com/@LeibnizLIV
• Facebookfacebook.com/leibnizLIV
• LinkedInlinkedin.com/company/leibniz-institut-fuer-virologie
• Instagraminstagram.com/LeibnizLIV

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Leibniz-Institut für Virologie